Holding back the sea: The role for maintenance chemotherapy in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 122, Issue 1, 2010, Pages 177-179

  Murphy, C G ^a   Khasraw, M ^a   Seidman, A D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIMETABOLITE; BSI 201; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; LIPOSOME; MACROGOL DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAINTENANCE THERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; CROSSOVER PROCEDURE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; METASTASIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); PARESTHESIA; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS-OVER STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOSOMES; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; PACLITAXEL; PARESTHESIA; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 77953541392     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0925-9     Document Type: Note

References (18)

1. I Smith 2006 Goals of treatment for patients with metastatic breast cancer Semin Oncol 33 1 Suppl 2 S2 S5 10.1053/j.seminoncol.2005.07.030 16472711
2. DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 783 792 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
3. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, et al (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 27(18 Suppl):(abstr 3)
4. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes, et al. 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 12 2812 2823 10.1200/JCO.2002.09.002 12065558 (Pubitemid 34651510)
5. KS Albain SM Nag G Calderillo-Ruiz JP Jordaan AC Llombart A Pluzanska, et al. 2008 Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 24 3950 3957 10.1200/JCO.2007.11.9362 18711184
6. GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky, et al. 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 4 588 592 10.1200/JCO.2003.08.013 12586793 (Pubitemid 46621890)
7. ES Thomas HL Gomez RK Li HC Chung LE Fein VF Chan, et al. 2007 Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment J Clin Oncol 25 33 5210 5217 10.1200/JCO.2007.12.6557 1:CAS:528:DC%2BD2sXhsVKnsbzO 17968020 (Pubitemid 350232252)
8. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez, et al. 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 26 2666 2676 10.1056/NEJMoa072113 1:CAS:528: DC%2BD1cXisVOnsg%3D%3D 18160686
9. A Sanchez-Munoz E Perez-Ruiz N Ribelles A Marquez E Alba 2008 Maintenance treatment in metastatic breast cancer Expert Rev Anticancer Ther 8 12 1907 1912 10.1586/14737140.8.12.1907 1:CAS:528:DC%2BD1cXhsVKgs7vN 19046111
10. B Ejlertsen P Pfeiffer D Pedersen HT Mouridsen C Rose M Overgaard, et al. 1993 Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months Eur J Cancer 29A 4 527 531 10.1016/S0959-8049(05)80145-5 1:STN:280: DyaK3s7mvVCntg%3D%3D 8435205
11. Gennari A, Sormani M, Bruzzi P, Wilcken N, Nanni O, Fornier M, et al (2008) A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). J Clin Oncol 26(May 20 Suppl):abstr 1067
12. A Coates V Gebski JF Bishop PN Jeal RL Woods R Snyder, et al. 1987 Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies N Engl J Med 317 24 1490 1495 1:STN:280:DyaL1c%2FmsFOntg%3D%3D 3683485
13. MA Nooij JC de Haes LV Beex J Wildiers J Klijn D Becquart, et al. 2003 Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists' preferences Eur J Cancer 39 5 614 621 10.1016/S0959-8049(02)00869-9 1:STN:280:DC%2BD3s7hsFCmuw%3D%3D 12628840 (Pubitemid 36287373)
14. Alba E, Ruiz-Borrego M, Margeli M, Rodriguez-Lescure A, Sanchez-Rovira P, Ruiz A, et al. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. doi: 10.1007/s10549-010- 0860-9
15. E Alba M Martin M Ramos E Adrover A Balil C Jara, et al. 2004 Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study J Clin Oncol 22 13 2587 2593 10.1200/JCO.2004.08.125 1:CAS:528:DC%2BD2cXpsVWksL8%3D 15226326 (Pubitemid 41103745)
16. A Gennari D Amadori M De Lena O Nanni P Bruzzi V Lorusso, et al. 2006 Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer J Clin Oncol 24 24 3912 3918 10.1200/JCO.2006.06.1812 1:CAS:528:DC%2BD28Xps1Sitrc%3D 16921042 (Pubitemid 46630739)
17. Mayordomo J, Baena J, Cirera L, Sanchez-Rovira P, Godes M, Galan A et al (2009) Final results of a randomized trial on the role of maintenance chemotherapy with weekly paclitaxel for patients with metastatic breast cancer. J Clin Oncol 27(15 suppl) (abstr 1001)
18. T Ciuleanu T Brodowicz C Zielinski JH Kim M Krzakowski E Laack, et al. 2009 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 9699 1432 1440 10.1016/S0140-6736(09)61497-5 1:CAS:528:DC%2BD1MXhtlSru7jL 19767093